NCT00689936 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 535
- group Id
- BG001
- value
- 541
- group Id
- BG002
- value
- 547
- group Id
- BG003
- value
- 1623
- units
- Participants
- groups
- description
- Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.
- id
- BG000
- title
- Lenalidomide and Low-Dose Dexamethasone (Rd)
- description
- Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.
- id
- BG001
- title
- Lenalidomide and Dexamethasone Rd18
- description
- Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.
- id
- BG002
- title
- Melphalan + Prednisone + Thalidomide (MPT)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.57
- value
- 73.2
- group Id
- BG001
- spread
- 6.50
- value
- 72.9
- group Id
- BG002
- spread
- 6.32
- value
- 73.1
- group Id
- BG003
- spread
- 6.46
- value
- 73.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 241
- group Id
- BG001
- value
- 268
- group Id
- BG002
- value
- 260
- group Id
- BG003
- value
- 769
- title
- Female
- measurements
- group Id
- BG000
- value
- 294
- group Id
- BG001
- value
- 273
- group Id
- BG002
- value
- 287
- group Id
- BG003
- value
- 854
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 127
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 20
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or other Pacific Islanders
- categories
- measurements
- group Id
- BG000
- value
- 474
- group Id
- BG001
- value
- 480
- group Id
- BG002
- value
- 491
- group Id
- BG003
- value
- 1445
- title
- White or Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 20
- title
- Other, Miscellaneous
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 9
- title
- Undisclosed
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 106
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 493
- group Id
- BG001
- value
- 505
- group Id
- BG002
- value
- 508
- group Id
- BG003
- value
- 1506
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- title
- Undisclosed
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 106
- group Id
- BG002
- value
- 103
- group Id
- BG003
- value
- 315
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 225
- group Id
- BG003
- value
- 681
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 202
- group Id
- BG001
- value
- 206
- group Id
- BG002
- value
- 219
- group Id
- BG003
- value
- 627
- title
- Stage III
- description
- International Staging System (ISS) is used as a staging system for multiple myeloma and divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Higher stages represent more advanced disease.
- param Type
- NUMBER
- title
- International Staging System (ISS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 155
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 156
- group Id
- BG003
- value
- 474
- title
- 0 (fully active)
- categories
- measurements
- group Id
- BG000
- value
- 257
- group Id
- BG001
- value
- 263
- group Id
- BG002
- value
- 275
- group Id
- BG003
- value
- 795
- title
- 1 (restrictive but ambulatory)
- categories
- measurements
- group Id
- BG000
- value
- 119
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 111
- group Id
- BG003
- value
- 343
- title
- 2 (ambulatory but unable to work)
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 6
- title
- 3-4 (limited self-care, completely disabled)
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 5
- title
- Missing
- description
- Eastern Cooperative Oncology Group (ECOG) Performance Status is used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 269
- group Id
- BG001
- value
- 280
- group Id
- BG002
- value
- 285
- group Id
- BG003
- value
- 834
- title
- >=60 ml/min
- categories
- measurements
- group Id
- BG000
- value
- 266
- group Id
- BG001
- value
- 261
- group Id
- BG002
- value
- 261
- group Id
- BG003
- value
- 788
- title
- <60 ml/min
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Missing
- param Type
- NUMBER
- title
- Creatinine clearance
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 224
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 682
- title
- >5.5 mg/L
- categories
- measurements
- group Id
- BG000
- value
- 309
- group Id
- BG001
- value
- 316
- group Id
- BG002
- value
- 312
- group Id
- BG003
- value
- 937
- title
- <=5.5 mg/L
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Missing
- param Type
- NUMBER
- title
- Beta2 Microglobulin
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 192
- group Id
- BG001
- value
- 209
- group Id
- BG002
- value
- 223
- group Id
- BG003
- value
- 624
- title
- <=35 g/L
- categories
- measurements
- group Id
- BG000
- value
- 343
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 324
- group Id
- BG003
- value
- 998
- title
- > 35 g/L
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Missing
- param Type
- NUMBER
- title
- Albumin
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 448
- group Id
- BG001
- value
- 442
- group Id
- BG002
- value
- 434
- group Id
- BG003
- value
- 1324
- title
- <200 U/L
- categories
- measurements
- group Id
- BG000
- value
- 86
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 112
- group Id
- BG003
- value
- 297
- title
- >=200 U/L
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Missing
- param Type
- NUMBER
- title
- Lactic Dehydrogenase
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 142
- group Id
- BG002
- value
- 123
- group Id
- BG003
- value
- 403
- title
- Immunoglobulin A
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 21
- title
- Immunoglobulin A and Immunoglobulin G
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Immunoglobulin A and Immunoglobulin M
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 15
- title
- Immunoglobulin D
- categories
- measurements
- group Id
- BG000
- value
- 334
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 350
- group Id
- BG003
- value
- 1015
- title
- Immunoglobulin G
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Immunoglobulin M
- categories
- measurements
- group Id
- BG000
- value
- 49
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 163
- title
- Not available (includes light-chain disease)
- param Type
- NUMBER
- title
- Multiple Myeloma Subtype
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 170
- group Id
- BG001
- value
- 185
- group Id
- BG002
- value
- 189
- group Id
- BG003
- value
- 544
- title
- Adverse Risk
- categories
- measurements
- group Id
- BG000
- value
- 112
- group Id
- BG001
- value
- 103
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 317
- title
- Favorable Hyperdiploidy
- categories
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 131
- group Id
- BG002
- value
- 141
- group Id
- BG003
- value
- 420
- title
- Normal
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 134
- title
- Uncertain Risk
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 113
- title
- Not evaluable
- categories
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 95
- title
- Missing
- description
- Cytogenetic risk categories are mutually exclusive. Definitions: Adverse risk category: t(4:14), t(14:16), del (13q) or monosomy 13, del (17p), 1q gain; Non-adverse risk categories include favorable hyperdiploidy: t(11:14), gains of 5/9/15; normal: a normal result, gains other than 5/9/15, IgH deletion, and uncertain risk: probes used for analysis cannot place participant in any risk categories. Not evaluable: no specimen received, test failure or insufficient number of cells available for analysis.
- param Type
- NUMBER
- title
- Cytogenetic Risk
- unit Of Measure
- Participants
- population Description
- Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 535
- group Id
- BG001
- value
- 541
- group Id
- BG002
- value
- 547
- group Id
- BG003
- value
- 1623
- units
- Participants
- groups
- description
- Participants ≤ 75 years old received 25 mg lenalidomide (R) administered by mouth (PO) on days 1 to 21 of each 28-day cycle plus 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants \> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone at the same schedule. Participants with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day on days 1-21 of each 28-day treatment cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle until disease progression or intolerable toxicity.
- id
- BG000
- title
- Lenalidomide and Low-Dose Dexamethasone (Rd)
- description
- Participants ≤ 75 years old received 25 mg lenalidomide (R) PO on days 1 to 21 of each 28-day treatment cycle 40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless progressive disease (PD) or intolerable toxicity occurred. Those \> 75 years old received lenalidomide 25 mg PO on the same schedule and frequency plus 20 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Those with moderate renal insufficiency received 10-15 mg lenalidomide (R) PO on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity. Participants with severe renal insufficiency received 15 mg lenalidomide (R) PO every other day (QOD) on days 1-21 of each 28-day cycle and 20-40 mg dexamethasone (d) PO on days 1, 8, 15, and 22 of a 28-day cycle for up to 18 cycles unless PD or intolerable toxicity.
- id
- BG001
- title
- Lenalidomide and Dexamethasone Rd18
- description
- Participants received melphalan (M) 0.25 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred. Participants with moderate to severe renal insufficiency received melphalan (M) 0.10-0.125 mg/kg PO daily (QD) on days 1 to 4 of each 42-day cycle plus prednisone (P) at 2 mg/kg PO on days 1 to 4 of each 42-day cycle and thalidomide 100-200 mg PO QD on days 1 to 41 of each 42-day cycle. MPT therapy was given for up to 12 cycles unless PD or intolerable toxicity occurred.
- id
- BG002
- title
- Melphalan + Prednisone + Thalidomide (MPT)
- description
- Total of all reporting groups
- id
- BG003
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- spread
- 6.57
- value
- 73.2
- group Id
- BG001
- spread
- 6.50
- value
- 72.9
- group Id
- BG002
- spread
- 6.32
- value
- 73.1
- group Id
- BG003
- spread
- 6.46
- value
- 73.1
- dispersion Type
- STANDARD_DEVIATION
- param Type
- MEAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 241
- group Id
- BG001
- value
- 268
- group Id
- BG002
- value
- 260
- group Id
- BG003
- value
- 769
- title
- Female
- measurements
- group Id
- BG000
- value
- 294
- group Id
- BG001
- value
- 273
- group Id
- BG002
- value
- 287
- group Id
- BG003
- value
- 854
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 40
- group Id
- BG001
- value
- 43
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 127
- title
- Asian
- categories
- measurements
- group Id
- BG000
- value
- 9
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 5
- group Id
- BG003
- value
- 20
- title
- Black or African American
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Native Hawaiian or other Pacific Islanders
- categories
- measurements
- group Id
- BG000
- value
- 474
- group Id
- BG001
- value
- 480
- group Id
- BG002
- value
- 491
- group Id
- BG003
- value
- 1445
- title
- White or Caucasian
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 11
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 20
- title
- Other, Miscellaneous
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 9
- title
- Undisclosed
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 37
- group Id
- BG001
- value
- 33
- group Id
- BG002
- value
- 36
- group Id
- BG003
- value
- 106
- title
- Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 493
- group Id
- BG001
- value
- 505
- group Id
- BG002
- value
- 508
- group Id
- BG003
- value
- 1506
- title
- Not Hispanic or Latino
- categories
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 11
- title
- Undisclosed
- param Type
- NUMBER
- title
- Race/Ethnicity, Customized
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 106
- group Id
- BG001
- value
- 106
- group Id
- BG002
- value
- 103
- group Id
- BG003
- value
- 315
- title
- Stage I
- categories
- measurements
- group Id
- BG000
- value
- 227
- group Id
- BG001
- value
- 229
- group Id
- BG002
- value
- 225
- group Id
- BG003
- value
- 681
- title
- Stage II
- categories
- measurements
- group Id
- BG000
- value
- 202
- group Id
- BG001
- value
- 206
- group Id
- BG002
- value
- 219
- group Id
- BG003
- value
- 627
- title
- Stage III
- description
- International Staging System (ISS) is used as a staging system for multiple myeloma and divides myeloma into 3 stages based only on the serum beta-2 microglobulin and serum albumin levels. Higher stages represent more advanced disease.
- param Type
- NUMBER
- title
- International Staging System (ISS)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 155
- group Id
- BG001
- value
- 163
- group Id
- BG002
- value
- 156
- group Id
- BG003
- value
- 474
- title
- 0 (fully active)
- categories
- measurements
- group Id
- BG000
- value
- 257
- group Id
- BG001
- value
- 263
- group Id
- BG002
- value
- 275
- group Id
- BG003
- value
- 795
- title
- 1 (restrictive but ambulatory)
- categories
- measurements
- group Id
- BG000
- value
- 119
- group Id
- BG001
- value
- 113
- group Id
- BG002
- value
- 111
- group Id
- BG003
- value
- 343
- title
- 2 (ambulatory but unable to work)
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 2
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 6
- title
- 3-4 (limited self-care, completely disabled)
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 5
- title
- Missing
- description
- Eastern Cooperative Oncology Group (ECOG) Performance Status is used to assess the progress of disease in a patient, how the disease affects the daily living abilities of the patient, and determine appropriate treatment and prognosis.
- param Type
- NUMBER
- title
- Eastern Cooperative Oncology Group (ECOG) Performance Status
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 269
- group Id
- BG001
- value
- 280
- group Id
- BG002
- value
- 285
- group Id
- BG003
- value
- 834
- title
- >=60 ml/min
- categories
- measurements
- group Id
- BG000
- value
- 266
- group Id
- BG001
- value
- 261
- group Id
- BG002
- value
- 261
- group Id
- BG003
- value
- 788
- title
- <60 ml/min
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Missing
- param Type
- NUMBER
- title
- Creatinine clearance
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 224
- group Id
- BG001
- value
- 224
- group Id
- BG002
- value
- 234
- group Id
- BG003
- value
- 682
- title
- >5.5 mg/L
- categories
- measurements
- group Id
- BG000
- value
- 309
- group Id
- BG001
- value
- 316
- group Id
- BG002
- value
- 312
- group Id
- BG003
- value
- 937
- title
- <=5.5 mg/L
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 4
- title
- Missing
- param Type
- NUMBER
- title
- Beta2 Microglobulin
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 192
- group Id
- BG001
- value
- 209
- group Id
- BG002
- value
- 223
- group Id
- BG003
- value
- 624
- title
- <=35 g/L
- categories
- measurements
- group Id
- BG000
- value
- 343
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 324
- group Id
- BG003
- value
- 998
- title
- > 35 g/L
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 1
- title
- Missing
- param Type
- NUMBER
- title
- Albumin
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 448
- group Id
- BG001
- value
- 442
- group Id
- BG002
- value
- 434
- group Id
- BG003
- value
- 1324
- title
- <200 U/L
- categories
- measurements
- group Id
- BG000
- value
- 86
- group Id
- BG001
- value
- 99
- group Id
- BG002
- value
- 112
- group Id
- BG003
- value
- 297
- title
- >=200 U/L
- categories
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- title
- Missing
- param Type
- NUMBER
- title
- Lactic Dehydrogenase
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 138
- group Id
- BG001
- value
- 142
- group Id
- BG002
- value
- 123
- group Id
- BG003
- value
- 403
- title
- Immunoglobulin A
- categories
- measurements
- group Id
- BG000
- value
- 7
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 8
- group Id
- BG003
- value
- 21
- title
- Immunoglobulin A and Immunoglobulin G
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 1
- title
- Immunoglobulin A and Immunoglobulin M
- categories
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 4
- group Id
- BG003
- value
- 15
- title
- Immunoglobulin D
- categories
- measurements
- group Id
- BG000
- value
- 334
- group Id
- BG001
- value
- 331
- group Id
- BG002
- value
- 350
- group Id
- BG003
- value
- 1015
- title
- Immunoglobulin G
- categories
- measurements
- group Id
- BG000
- value
- 3
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 5
- title
- Immunoglobulin M
- categories
- measurements
- group Id
- BG000
- value
- 49
- group Id
- BG001
- value
- 54
- group Id
- BG002
- value
- 60
- group Id
- BG003
- value
- 163
- title
- Not available (includes light-chain disease)
- param Type
- NUMBER
- title
- Multiple Myeloma Subtype
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 170
- group Id
- BG001
- value
- 185
- group Id
- BG002
- value
- 189
- group Id
- BG003
- value
- 544
- title
- Adverse Risk
- categories
- measurements
- group Id
- BG000
- value
- 112
- group Id
- BG001
- value
- 103
- group Id
- BG002
- value
- 102
- group Id
- BG003
- value
- 317
- title
- Favorable Hyperdiploidy
- categories
- measurements
- group Id
- BG000
- value
- 148
- group Id
- BG001
- value
- 131
- group Id
- BG002
- value
- 141
- group Id
- BG003
- value
- 420
- title
- Normal
- categories
- measurements
- group Id
- BG000
- value
- 38
- group Id
- BG001
- value
- 56
- group Id
- BG002
- value
- 40
- group Id
- BG003
- value
- 134
- title
- Uncertain Risk
- categories
- measurements
- group Id
- BG000
- value
- 34
- group Id
- BG001
- value
- 35
- group Id
- BG002
- value
- 44
- group Id
- BG003
- value
- 113
- title
- Not evaluable
- categories
- measurements
- group Id
- BG000
- value
- 33
- group Id
- BG001
- value
- 31
- group Id
- BG002
- value
- 31
- group Id
- BG003
- value
- 95
- title
- Missing
- description
- Cytogenetic risk categories are mutually exclusive. Definitions: Adverse risk category: t(4:14), t(14:16), del (13q) or monosomy 13, del (17p), 1q gain; Non-adverse risk categories include favorable hyperdiploidy: t(11:14), gains of 5/9/15; normal: a normal result, gains other than 5/9/15, IgH deletion, and uncertain risk: probes used for analysis cannot place participant in any risk categories. Not evaluable: no specimen received, test failure or insufficient number of cells available for analysis.
- param Type
- NUMBER
- title
- Cytogenetic Risk
- unit Of Measure
- Participants
- population Description
- Intent to Treat (ITT) population includes all participants who were randomized, independent of whether they received study treatment or not
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle